Scientific Publications

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation.

Publication TypeJournal Article
AuthorsBejar, R., Stevenson KE, Caughey B., Lindsley RC, Mar BG, Stojanov P., Getz G., Steensma DP, Ritz J., Soiffer R., Antin JH, Alyea E., Armand P., Ho V., Koreth J., Neuberg D., Cutler CS, and Ebert BL
AbstractRecurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with MDS is not known.
Year of Publication2014
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Date Published (YYYY/MM/DD)2014/08/04
ISSN Number0732-183X
DOI10.1200/JCO.2013.52.3381
PubMedhttp://www.ncbi.nlm.nih.gov/pubmed/25092778?dopt=Abstract